Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that has been in the spotlight recently as one of the cheap NASDAQ stocks to buy according to hedge funds. With a forward P/E ratio of 13.24 and 74 hedge fund holders, Gilead is making waves in the industry.
In a recent interview on CNBC, Dan Ives, Head of Global Tech Research at Wedbush Securities, discussed the current state of the tech sector, highlighting the potential for major volatility ahead. The uncertainty in the tech industry has been exacerbated by escalating tariffs on China, reaching as high as 125%. This has forced companies to rethink their supply chains and has resulted in a noticeable pause in tech spending.
Despite the challenges, Ives has not downgraded tech stocks, emphasizing the potential for clear winners to emerge from the current turmoil. He predicts that Street estimates are likely to see earnings cuts of about 10% across internet and big tech companies, reflecting the broader pullback in spending and ongoing volatility.
Gilead Sciences has seen success in its HIV franchise, with sales reaching $19.6 billion in 2024. Key products like Biktarvy and Descovy have contributed to this growth, solidifying Gilead’s position in the market. While the company expects some temporary challenges in 2025 due to Medicare Part D reform, the underlying HIV business remains strong.
In a recent investor letter, ClearBridge Value Strategy praised Gilead’s performance, citing strong fourth-quarter earnings growth and positive reception to its new treatments. Overall, Gilead ranks 9th on the list of cheap NASDAQ stocks to buy according to hedge funds.
While Gilead shows promise, there are other opportunities in the market, particularly in AI stocks. These stocks have the potential to deliver high returns in a shorter time frame. If you’re looking for an AI stock with significant growth potential, consider exploring the cheapest AI stock highlighted in our report.
In conclusion, Gilead Sciences is positioned as a strong contender in the biopharmaceutical industry, with a solid track record and promising future prospects. However, investors should also consider exploring opportunities in AI stocks for potentially higher returns. Stay informed and make informed investment decisions based on the latest market trends and opportunities.